Comparer des méthodes
Examinez les méthodes sélectionnées côte à côte ; les lignes qui diffèrent sont mises en évidence.
| La liste des symptômes limites (BSL-95)× | Échelle d'évaluation des syndromes positif et négatif (PANSS)× | |
|---|---|---|
| Domaine | Psychiatrie | Psychiatrie |
| Famille | Process / pipeline | Process / pipeline |
| Année d'origine≠ | 2007 | 1987 |
| Auteur d'origine≠ | Martin Bohus | Stanley R. Kay |
| Type≠ | Self-report questionnaire | Clinician-administered rating scale |
| Source fondatrice≠ | Bohus, M., Kleindienst, N., Limberger, M. F., Stieglitz, R. D., Domsalla, M. E., Chapman, A. L., ... & Wolf, M. (2009). The short version of the Borderline Symptom List (BSL-23): Development and initial data on psychometric properties. Psychopathology, 42(1), 32–39. DOI ↗ | Kay, S. R., Fiszbein, A., & Opler, L. A. (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin, 13(2), 261–276. DOI ↗ |
| Alias≠ | BSL, BSL-95, Borderline Symptom List-95 | PANSS |
| Apparentées | 3 | 3 |
| Résumé≠ | The BSL-95 is a 95-item self-report questionnaire designed to measure the severity of borderline personality disorder (BPD) symptoms across nine subscales: affect dysregulation, distrust, self-harming behaviors, suicide risk, identity disturbance, negative relationships, and dissociation. Developed by Bohus and colleagues in 2007, it provides comprehensive assessment of the multifaceted psychopathology of BPD. A brief 23-item version (BSL-23) has also been validated for rapid assessment. The BSL is sensitive to treatment effects and widely used in BPD research and clinical monitoring. | The PANSS is a 30-item clinician-administered scale designed to measure the presence and severity of positive symptoms (delusions, hallucinations, disorganization), negative symptoms (affective flattening, alogia, avolition), and general psychopathology in schizophrenia and related psychotic disorders. Developed by Kay, Fiszbein, and Opler in 1987, the PANSS has become the standard rating scale in schizophrenia research, antipsychotic medication trials, and clinical monitoring. It provides comprehensive assessment across three symptom domains and yields a total score reflecting overall disease severity. |
| ScholarGateJeu de données ↗ |
|
|